Abstract

Here, we evaluated whether the overexpression of transcriptionally inactive ΔNp73 cooperates with PML/RARA fusion protein in the induction of an APL-leukemic phenotype, as well as its role in vitro in proliferation, myeloid differentiation, and drug-induced apoptosis. Using lentiviral gene transfer, we showed in vitro that ΔNp73 overexpression resulted in increased proliferation in murine bone marrow (BM) cells from hCG-PML/RARA transgenic mice and their wild-type (WT) counterpart, with no accumulation of cells at G2/M or S phases; instead, ΔNp73-expressing cells had a lower rate of induced apoptosis. Next, we evaluated the effect of ΔNp73 on stem-cell self-renewal and myeloid differentiation. Primary BM cells lentivirally infected with human ΔNp73 were not immortalized in culture and did not present significant changes in the percentage of CD11b. Finally, we assessed the impact of ΔNp73 on leukemogenesis or its possible cooperation with PML/RARA fusion protein in the induction of an APL-leukemic phenotype. After 120 days of follow-up, all transplanted mice were clinically healthy and, no evidence of leukemia/myelodysplasia was apparent. Taken together, our data suggest that ΔNp73 had no leukemic transformation capacity by itself and apparently did not cooperate with the PML/RARA fusion protein to induce a leukemic phenotype in a murine BM transplantation model. In addition, the forced expression of ΔNp73 in murine BM progenitors did not alter the ATRA-induced differentiation rate in vitro or induce aberrant cell proliferation, but exerted an important role in cell survival, providing resistance to drug-induced apoptosis.

Highlights

  • In the clinical setting, high expression of the NH2terminal truncated ΔNp73 isoforms has been associated with poor prognosis in primary human tumors [1,2,3], including hematological malignancies [4,5,6]

  • We showed in vitro that ΔNp73 overexpression resulted in increased proliferation in murine bone marrow (BM) cells from hCG-PML/RARA transgenic mice and their wild-type (WT) counterpart, with no accumulation of cells at G2/M or S phases; instead, ΔNp73-expressing cells had a lower rate of induced apoptosis

  • [7], we demonstrated that a high ΔNp73/TAp73 ratio is associated with inferior outcome in patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy according to the International Consortium on APL 2005 protocol [8]

Read more

Summary

INTRODUCTION

High expression of the NH2terminal truncated ΔNp73 isoforms (alone or in association with full-length transcriptionally active TAp73, i.e., a high ΔNp73/TAp73 ratio) has been associated with poor prognosis in primary human tumors [1,2,3], including hematological malignancies [4,5,6]. [7], we demonstrated that a high ΔNp73/TAp73 ratio is associated with inferior outcome in patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy according to the International Consortium on APL 2005 protocol [8]. The mechanism through which ΔNp73 leads to adverse outcomes in APL remains to be elucidated and if ΔNp73 works as a driver oncogene in APL is unknown. We investigated the role of ΔNp73 in proliferation, myeloid differentiation, and drug-induced apoptosis

RESULTS AND DISCUSSION
MATERIALS AND METHODS
CONFLICTS OF INTEREST
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call